摘要
目的 异基因非清髓与清髓造血干细胞移植临床研究。方法 对2组移植在造血重建、嵌舍体形成、供者淋巴细胞输注（DLI）及复发、GVHD、感染及其他并发症等方面比较。结果 移植后造血重建时间2组差异无统计学意义。非清髓组有6例出现嵌合体的变化；清髓组均以完全嵌合体形式植入。非清髓组复发率高于清髓组，经DLI能有效控制。非清髓组有1例Ⅳ度急性移植物抗宿主病（aGVHD），4例经DLI诱发慢性GVHD（cGVHD）；清髓组有6例Ⅰ～Ⅱ度aGVHD，2例cGVHD。非清髓组无1例发生早期感染，清髓组有7例。清髓组并发症与预处理毒性有关，非清髓组则与移植前患者的伴发症有关。非清髓组2例死亡，清髓组1例死亡。结论 非清髓移植较清髓移植更适用于年龄较大、身体状况不好的患者.
Objective To do a comparative study between nonmyeloablative and myoeloablative hematopoietic stem cell transplantation （HSCT） on clinic. Methods Hematopoietic recovery, formation of chimera, donor lymphocyte infusion （DLI） and relapse, GVHD,infection and other complication were retrospectively analyzed between the two groups. Results After transplantation ,there was no difference at the media hematopoietic recovery time between the two groups. Six patients received NST appeared changes in the chimera. The full donor chimera was detected in all patients received myeloablative transplantation. Nonmyeloablatinve group was easier to relapse than myeloablative group, but DLI was valid, tn nonmyeloablative group, one had grade Ⅳ aGVHD and cGVHD was observed in 4 patients by DLI;While there were 6 grade Ⅰ -Ⅱ aGVHD patients and 2 cGVHD. In early period, no infection occurred in nonmyeloablative group while 7 had infectious disease in myeloablative group. Complication in myeloablative group related to the toxicity of regimen while in nonmyeloablative group related to the disease occurred before transplant. Two was dead in nonmyeloablative group. And 1 died in myeloablative group. Conclusions NST allow transplant in elderly or medically infirm patients.
出处
《实用全科医学》
2007年第9期763-764,共2页
Applied Journal Of General Practice
关键词
非清髓造血干细胞移植
供者淋巴细胞输注
造血重建
移植物抗宿主病
Nonmyeloablative hematopoietic stem cell transplantation
Donor lymphocyte infusion
Hematopoietic recovery
Graft versus host disease
